[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100430646":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":97,"collaborators":101,"id":104,"slug":105,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":106,"sex":112,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":29,"studyType":118,"phases":119,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":45,"whyStopped":29,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Acetazolamide","ACTIVE_COMPARATOR","acetazolamide capsules",[13],"Drug: Acetazolamide",{"label":15,"type":10,"description":16,"interventionNames":17},"Placebo","Identical gelatin capsules",[18],"Drug: Placebo",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","ACZ 250 mg\u002Fday in gelatin capsules will be administered initially and increased over 7-10 days to 2g\u002Fday.",[9],[25],"Diamox",{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":29},"Identical gelatin capsules will be prepared by filling with inert excipients.",[15],null,[31],{"name":32,"affiliation":5,"role":33},"Vishwajit L Nimgaonkar, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":29,"email":38},"CONTACT","412-246-6356","vishwajitNL@upmc.edu",{"name":40,"role":36,"phone":41,"phoneExt":29,"email":42},"Maribeth A Wesesky, BPS","4122957017","weseskyma@upmc.edu",[44,72],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Pittsburgh","Pennsylvania","15213","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-79.99589,40.44062,{"lat":55,"lon":54},[58,60,63,65,66,68,70],{"name":40,"role":36,"phone":59,"phoneExt":29,"email":42},"412-295-7017",{"name":61,"role":62,"phone":29,"phoneExt":29,"email":29},"Satish Iyengar, Ph.D.","SUB_INVESTIGATOR",{"name":64,"role":62,"phone":29,"phoneExt":29,"email":29},"Konasale Prasad, M.D.",{"name":40,"role":62,"phone":29,"phoneExt":29,"email":29},{"name":67,"role":62,"phone":29,"phoneExt":29,"email":29},"Ian Conner, M.D.",{"name":69,"role":62,"phone":29,"phoneExt":29,"email":29},"Madhavi K Ganapathiraju, Ph.D.",{"name":71,"role":62,"phone":29,"phoneExt":29,"email":29},"Roy KN Chengappa, M.D.",{"facility":73,"status":45,"city":74,"state":29,"zip":29,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"St John's Medical College Hospital","Bangalore","India","IN",{"type":52,"coordinates":78},[79,80],77.59369,12.97194,{"lat":80,"lon":79},[83,87,91,93,95],{"name":84,"role":36,"phone":85,"phoneExt":29,"email":86},"Smita N Deshpande, M.D.","(91)- 93126-54702","smitadeshp@gmail.com",{"name":88,"role":36,"phone":89,"phoneExt":29,"email":90},"Triptish Bhatia, Ph.D.","(91)-11-23404363","bhatiatriptish@yahoo.co.in",{"name":92,"role":62,"phone":29,"phoneExt":29,"email":29},"Ashok Mysore, M.D.",{"name":94,"role":62,"phone":29,"phoneExt":29,"email":29},"Anil Kakunje, M.D.",{"name":96,"role":33,"phone":29,"phoneExt":29,"email":29},"Smita Deshpande, M.D.",{"type":98,"investigatorFullName":99,"investigatorTitle":100,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"SPONSOR_INVESTIGATOR","Vishwajit Nimgaonkar, MD PhD","Professor of Psychiatry and Human Genetics",[102],{"name":103,"class":6},"Stanley Medical Research Institute","100430646","phase-1-acetazolamide-for-treatment-resistant-schizophrenia-100430646",false,"NCT04887792","Acetazolamide for Treatment Resistant Schizophrenia","A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia","APTS","Inclusion Criteria:\n\n* Written informed consent.\n* Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).\n* PANSS total score \\> 60 and Score \\> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.\n* Stable dose of antipsychotic drug (APD) for \\> 1 month, continued throughout the study.\n* Not participating in another randomized controlled clinical trial (RCT).\n\nExclusion Criteria:\n\n* Substance abuse in the past month\u002Fdependence past 6 months with the exception of methadone prescribed for opiate withdrawal.\n* History or current medical\u002Fneurological illnesses that may lead to unstable course, e.g., epilepsy.\n* Pregnancy.\n* Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease\u002Fadrenal failure; chronic closed angle-closure glaucoma.\n* Current or prior treatment with ACZ or history of hypersensitivity to ACZ.\n* Intellectual disability as defined in DSM 5.","ALL","18 Years","55 Years",{"count":116,"type":117},60,"ESTIMATED","INTERVENTIONAL",[120,121],"PHASE1","PHASE2","This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.",[124,125],"Schizophrenia","Schizo Affective Disorder",[124,125,127],"acetazolamide","2026-04-06",{"date":130,"type":131},"2026-04-07","ACTUAL",{"date":133,"type":131},"2022-02-01",{"date":135,"type":117},"2026-12-30",{"name":99,"class":6},2]